Front Pharmacol. 2021 May 14;12:630904.
Sonja E Zapke, Stefan Willmann, Scott-Oliver Grebe, Kristin Menke, Petra A Thürmann, Sven Schmiedl
https://pubmed.ncbi.nlm.nih.gov/34054518/
Abstract
This study compared simulations of a physiologically based pharmacokinetic (PBPK) model implemented for cyclosporine with drug levels from therapeutic drug monitoring to evaluate the predictive performance of a PBPK model in a clinical population. Based on a literature search model parameters were determined. After calibrating the model using the pharmacokinetic profiles of healthy volunteers, 356 cyclosporine trough levels of 32 renal transplant outpatients were predicted based on their biometric parameters. Model performance was assessed by calculating absolute and relative deviations of predicted and observed trough levels. The median absolute deviation was 6 ng/ml (interquartile range: 30 to 31 ng/ml, minimum = -379 ng/ml, maximum = 139 ng/ml). 86% of predicted cyclosporine trough levels deviated less than twofold from observed values. The high intra-individual variability of observed cyclosporine levels was not fully covered by the PBPK model. Perspectively, consideration of clinical and additional patient-related factors may improve the model's performance. In summary, the current study has shown that PBPK modeling may offer valuable contributions for pharmacokinetic research in clinical drug therapy.
Keywords: PBPK; cyclosporine; modeling and simulation; pharmacokinetics; therapeutic drug monitoring.
Front Pharmacol. 2021 May 14;12:630904. Sonja E Zapke, Stefan Willmann, Scott-Oliver Grebe, Kristin Menke, Petra A Thürmann, Sven Schmiedl https://pubmed.ncbi.nlm.nih.gov/34054518/
Abstract This study compared simulations of a physiologically based pharmacokinetic (PBPK) model implemented for cyclosporine with drug levels from therapeutic drug monitoring to evaluate the predictive performance of a PBPK model in a clinical population. Based on a literature search model parameters were determined. After calibrating the model using the pharmacokinetic profiles of healthy volunteers, 356 cyclosporine trough levels of 32 renal transplant outpatients were predicted based on their biometric parameters. Model performance was assessed by calculating absolute and relative deviations of predicted and observed trough levels. The median absolute deviation was 6 ng/ml (interquartile range: 30 to 31 ng/ml, minimum = -379 ng/ml, maximum = 139 ng/ml). 86% of predicted cyclosporine trough levels deviated less than twofold from observed values. The high intra-individual variability of observed cyclosporine levels was not fully covered by the PBPK model. Perspectively, consideration of clinical and additional patient-related factors may improve the model's performance. In summary, the current study has shown that PBPK modeling may offer valuable contributions for pharmacokinetic research in clinical drug therapy.
Keywords: PBPK; cyclosporine; modeling and simulation; pharmacokinetics; therapeutic drug monitoring.
Copyright © 2021 Zapke, Willmann, Grebe, Menke, Thürmann and Schmiedl.